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Abstract
In Parkinson’s disease (PD), alpha-synuclein (a-syn) can be detected in biological fluids
including saliva. Although previous studies found reduced a-syn total (a-syntotal) concentra-
tion in saliva of PD patients, no studies have previously examined salivary a-syn oligomers
(a-synolig) concentrations or assessed the correlation between salivary a-syntotal, a-synolig
and clinical features in a large cohort of PD patients. Is well known that a-synolig exerts a
crucial neurotoxic effect in PD. We collected salivary samples from 60 PD patients and 40
age- and sex-comparable healthy subjects. PD was diagnosed according to the United
Kingdom Brain Bank Criteria. Samples of saliva were analyzed by specific anti-a-syn and
anti-oligomeric a-syn ELISA kits. A complete clinical evaluation of each patient was per-
formed using MDS-Unified Parkinson's Disease Rating Scale, Beck Depression Inventory,
Montreal Cognitive Assessment and Frontal Assessment Battery. Salivary a-syntotal was
lower, whereas a-synolig was higher in PD patients than healthy subjects. The a-synolig/a-
syntotal ratio was also higher in patients than in healthy subjects. Salivary a-syntotal concen-
tration negatively correlated with that of a-synolig and correlated with several patients’ clini-
cal features. In PD, decreased salivary concentration of a-syntotal may reflect the reduction
of a-syn monomers (a-synmon), as well as the formation of insoluble intracellular inclusions
and soluble oligomers. The combined detection of a-syntotal and a-synolig in the saliva might
help the early diagnosis of PD.
Introduction
Alpha-synuclein (a-syn) is a 140-amino acid protein that is widely expressed in presynaptic ter-
minals of the central nervous system and plays an important role in the pathogenesis of Parkin-
son’s disease (PD) [1,2]. PD is pathologically characterized by a-syn deposition into neurons
and neuronal fibers, which leads to the formation of Lewy Bodies and Lewy Neurities [2,3]. In
physiological conditions, a-syn is prevalently expressed as a monomeric form (a-synmon) [4]
and is localized in the cytoplasm and in the cellular nuclei or bound to the synaptic vesicles
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[5,6]. In PD, a-synmon aggregates into a-syn oligomers (a-synolig) and the oligomers formation,
in turn, is followed by oligomers conversion into mature amyloid fibrils, leading to the forma-
tion of Lewy bodies and Lewy neurities [7,8]. Soluble a-synolig are present in larger amounts in
brain homogenates of PD patients than in those of healthy subjects [9] and cause neuronal cell
death [10], being therefore the main neurotoxic form of a-syn [7,11,12].
Previous studies have investigated a-syn in cerebrospinal fluid (CSF) [13,14,15,16] and in
peripheral nerve fibers in biopsies of non-nervous tissues, including gut [17,18,19] and skin
[20,21]. A-syn aggregation has also been described in minor salivary glands [22], though no
significant difference emerged between PD patients and healthy subjects. By contrast, a-syn
aggregation is present in the nervous fibers that innervate the sub-mandibular gland, in PD
patients but not in healthy subjects [23].
Saliva is a biological fluid that can easily be collected. Previous studies have investigated a-
syn in saliva. Devic and coworkers [24] found that differences in a-syn levels between patients
with PD and healthy subjects were not significant, although a trend pointing to lower a-syn lev-
els in PD patients than in healthy subjects was detected. Al-Nimer et al.[25] instead reported
that a-syn levels were significantly lower in the saliva of patients with PD than in healthy sub-
jects. Both these studies were performed on small groups of patients with PD and neither inves-
tigated a-synolig. Several studies based on CSF have reported that a-synolig levels are
significantly higher in patients with PD than in healthy subjects [9,26,27], which suggests that
a-synolig might be a more reliable diagnostic indicator than total a-syn alone.
The diagnosis of PD is based on clinical criteria [28,29] whose accuracy may be limited, par-
ticularly in the early stages of the disease. A validated biomarker would help the clinical diagno-
sis of PD. Since a-syntotal and a-synolig in peripheral tissues and biological fluids are potential
biomarkers of PD, the detection of a-syn in saliva may offer a promising means of molecular
diagnosing of PD.
The aim of the present study was to investigate, in a large cohort of PD patients and healthy
subjects, a-syntotal and a-synolig levels in saliva to assess whether salivary a-syn can be used to
differentiate PD patients from healthy subjects, and whether a-syntotal and a-synolig concentra-
tions correlate with the clinical scores of PD patients. Therefore, we tested a-syn in a group of




After receiving a full explanation of the aims of the study, participants (both patients and
healthy subjects) gave their written informed consent. The consent form was previously
approved by the Institutional Review Board of the Sapienza University of Rome. The study was
approved by the Ethical Commmitte of the Sapienza University of Rome and all clinical inves-
tigations are conformed to the Declaration of Helsinki.
Sixty patients with PD (31 males, 29 females; mean age ±SD: 66.3±8.78, range 53–82 years;
mean±SD age at onset: 60.4±9.2, range 28–77 years) were recruited at the Movement Disorders
outpatient clinic of the Department of Neurology and Psychiatry, Sapienza University of
Rome, Italy. Forty healthy subjects, who were age- and sex-comparable with the PD patients
(22 males, 18 females; mean age±SD: 68.3±7.9, range 51–83 years), were also enrolled in the
study. We designed to enroll a total number of 60 patients with PD and 40 healthy subjects on
the basis of a preliminary statistical power analysis (sample size estimation) that demonstrated
a minimum number of at least 40 participants to reach statistical significant differences when
comparing the two groups. Diagnosis of PD was based on the Queen Square Brain Bank
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Criteria [28,29]. PD diagnosis was also confirmed with follow-up clinical evaluations [29].
Demographic and clinical information was collected through a face-to-face questionnaire (S1
Table), and a complete neurological examination was performed. The data collected for each
patient included: stage of the disease, scored with the Hoehn & Yahr scale (HY); severity of dis-
ease, assessed with the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) (part
1–4); mood, assessed with the Beck Depression Inventory (BDI-II); cognitive impairment,
assessed with the Montreal Cognitive Assessment (MOCA) and the Frontal Assessment Bat-
tery (FAB). Current pharmacological treatment for PD was also assessed and calculated as
L-Dopa equivalent daily dose (LEDD), for each drug, as previously reported [30]. We calcu-
lated LEDDs in order to avoid methodological biases due to the large variability in drug sub-
classes taken by the different patients. Patients were clinically evaluated while they were under
their usual medical treatment and were in their ON state. Patients affected by atypical or sec-
ondary parkinsonisms were excluded from the study. All patients enrolled in the study had a
MOCA score higher than 18 and a FAB score higher than 12 [31,32]. Participants (whether
patients or healthy subjects) affected by cardiovascular and cerebrovascular diseases, diabetes
mellitus, autoimmune diseases, chronic inflammatory diseases, hematological neoplasms and
solid tumors were also excluded from this study, as well subjects affected by salivary gland and
oral cavity pathologies.
Sample collection
We collected a minimum quantity of 3 ml of saliva from each PD patient and healthy subject.
At the time of collection of the saliva sample, subjects had fasted for 60 minutes, had not
smoked in the preceding 4 hours and had not drunk alcohol in the previous 12 hours. Samples
with blood contamination were excluded from the study. Saliva was collected by instructing
the patients to drool into a 50 ml vial, which was immediately placed on ice in order to block
proteolytic activity.
Samples were then placed in 10 ml falcon-type tubes and centrifuged for 15 min at 2,600 x g
at 4°C to obtain a first clarification, and then for another 15 min at 15,000 x g at 4°C to remove
residual particles, such as bacteria and desquaming mucosal cells. After centrifugation, the
supernatant was transferred into new 10 ml falcon-type tubes and each sample was treated
with a protease activity-inhibiting buffer (Sigma Aldrich, St.Luis, MO, USA, Cat #P2714), at a
concentration of 100 μL for 1 ml of saliva. Each sample was then transferred into a 1 ml Hep-
pendorf-type test tube, thus providing six 300 μl-samples from each patient. Samples were
stored at -80° before the ELISA investigation. The samples were collected according to the pro-
tocol adopted by Devic and coworkers [24] in previous works on saliva.
To verify possible changes in salivary a-syn concentration (a-syntotal and a-synolig) in inde-
pendent samples, we also collected 2 independent sample sets in the same day (8 a.m. and 4 p.
m.) in a subgroup of 10 healthy subjects and 10 patients with PD. Finally, to verify the consis-
tency of our analytical results, we have also measured a-syn concentration two times in the
same salivary sample in the same subgroup of 10 healthy subjects and 10 patients with PD.
ELISA analysis of samples
Samples were analyzed at the laboratory of Immunohistochemistry of the Department of
Human Anatomy, Sapienza University of Rome.
A-syntotal and a-synolig were assessed in saliva by enzyme immunoassay (ELISA). The con-
centration of the protein was determined by spectrometric measurement at 450 nm in an
appropriate microplate reader. We used this method to draw a standard curve based on the
optical density resulting from the presence of a-syntotal and of a-synolig in the samples, and we
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calculated the concentration of the two protein variants in each sample. Each standard curve of
optical density corresponds to each optical density value of a specific value in the pg or ng of
the protein concentration. This method allowed us to achieve a range of linearity based on the
concentration of a-syntotal and a-synolig, and a range of concentration values that could be used
to differentiate patients with PD from healthy subjects.
We used the anti-alpha-Synuclein Quantitative ELISA Kit (SensoLyte 55550) to determine
a-syntotal. The ELISA kit has been already used to determine a-syntotal in saliva in a previous
study in patients with PD [25]. To determine a-synolig we used the Human a-syn oligomer
ELISA Kit (MyBioSource, MBS730762). This ELISA kit is specific for detecting a-synolig, with a
very low cross-reactivity for a-synmon (for detailed information: data in S1 Text, by courtesy of
MyBioSource lab. Inc., San Diego, CA).
Each sample from PD patient and healthy subject has been analyzed in three different wells
and the results are the averaged a-syntotal and a-synolig concentration from the three different
wells.
During ELISA analysis, we cautiously used all the methodological precautions to minimize
“in vitro” aggregation or disaggregation of a-synolig, including stable physical conditions during
all experimental procedures (pH 7.44, temperature 37°C, 0,9% electrolyte concentrations of
solutions).
Data analysis and atatistics
Each optical density value, obtained from the ELISA test, was normalized with the optical den-
sity of blank controls. Concentrations of a-syntotal and a-synolig were calculated following the
linearity curve obtained in the ELISA test. The a-synolig/a-syntotal ratio was calculated in each
patient and healthy subject.
Mann-Whitney U test was used to compare the salivary concentration of a-syntotal (pg/ml),
a-synolig (ng/ml) and the a-syntotal/a-synolig ratio in patients with PD and healthy subjects.
Data are presented in linear bar diagrams. Mann-Whitney U test was also used to compare the
salivary concentration of a-syntotal and a-synolig in the 2 independent sample sets, collected in
the same day (8 a.m. and 4 p.m.), in the subgroup of 10 healthy subjects and 10 PD patients.
Finally, Mann-Whitney U test was again used to compare the salivary concentration of a-synto-
tal and a-synolig, measured in two independent experiments on the same salivary sample, in the
same subgroup of 10 healthy subjects and 10 PD patients.
The Spearman's Rank Correlation Coefficient was used to detect any correlations between
the PD patients’ clinical data, including age, disease duration, H&Y, MDS-UPDRS (part 1–4),
BDI-II, MOCA, FAB and LEDD, and the biochemical analysis. Holm’s correction for multiple
comparisons was used to discover false significance. P values<0.05 were considered to indicate
statistical significance.
Results
The cohort of patients with PD we studied had a mean disease duration of 6.7±10.4 years, an
H&Y score of 1.8±0.75. The MDS-UPDRS score was 9.18±5.95 (part 1); 9.93±9.8 (part 2); 23.7
±15.48 (part 3) and 2.2±4.3 (part 4). BDI-II score was 10.55±7.54, MOCA score was 26.08
±2.59, FAB score was 16.91±1.44 and finally, LEDD was 460±179.81 mg/day (S1 Table).
The Mann-Whitney U test revealed significant lower α-syntotal levels in the saliva of patients
with PD than in that of healthy subjects (z = -7.98; p<0.01, Fig 1A). A-syntotal levels in the
saliva were 5.08±3.01ρg/ml in patients with PD and 31.3±22.4 ρg/ml in healthy subjects. By
contrast, the Mann-Whitney U test showed that α-synolig was significantly higher in the saliva
of patients with PD than in that of healthy subjects (z = -7.82; p<0.01, Fig 1B). The average α-
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synolig concentration was 1.062±0.266 ng/ml in patients with PD and 0.498±0.203 ng/ml in
healthy subjects. The Mann-Whitney U test also revealed comparable salivary concentration of
a-syntotal and a-synolig in the 2 independent sample sets, collected in the same day (8 a.m. and 4
p.m.), in the subgroup of healthy subjects and PD patients (all p values< 0.05). Finally, the
Mann-Whitney U test again revealed comparable salivary concentration of a-syntotal and a-
synolig, measured in two independent experiments on the same salivary sample, in the same
subgroup of 10 healthy subjects and 10 PD patients (all p values< 0.05).
The α-synolig/α-syntotal ratio was significantly higher in patients with PD than in healthy
subjects (z = -8.30; p<0.01, Fig 1C). The mean ratio in patients with PD was 0.174±0.044,
whereas the mean ratio in healthy subjects was 0.065±0.027.
The Spearman's Rank Correlation Coefficient revealed a negative correlation between α-
syntotal and α-synolig (r = -0.25; p = 0.05; Fig 1D), a positive correlation between α-syntotal and
Fig 1. Salivary a-synuclein in PD patients and healthy subjects. Salivary a-syn in patients with Parkinson’s disease (PD) and healthy subjects (HS). Each
histogram corresponds to the mean concentration of α-syntotal (panel A), α-synolig (panel B) and the α-syntotal/α-synolig ratio (panel C) in the saliva of patients
with PD (black histogram) and HS (white histogram). Vertical bars denote standard deviation. Asterisk denote significant differences. Scatter-plot (panel D)
shows the negative correlation between α-syntotal and α-synolig in patients with PD.
doi:10.1371/journal.pone.0151156.g001
Alpha-Synuclein in Saliva
PLOS ONE | DOI:10.1371/journal.pone.0151156 March 24, 2016 5 / 12
disease duration (r = 0.31; p = 0.02; Fig 2A), H&Y (r = 0.29; p = 0.02) and MDS-UPDRS total
score (part 1–4) (r = 0.25; p = 0.05; Fig 2B). Spearman's Rank Correlation Coefficient revealed a
trend for a positive correlation between α-syntotal andMDS-UPDRS part 2 (r = 0.23; p = 0.07)
and part 4 scores (r = 0.24; p = 0.06), whereas it failed to detect any significant correlation with
MDS-UPDRS part 1 (r = 0.15; p = 0.26) and part 3 scores (r = 0.20; p = 0.11). Spearman's Rank
Correlation Coefficient also found a positive correlation between α-syntotal and LEDD (r = 0.4;
p<0.01), and a negative correlation, between α-syntotal andMOCA (r = -0.3; p = 0.02; Fig 2C)
and FAB scores (r = -0.32; p = 0.01; Fig 2D). Finally, the Spearman's Rank Correlation Coefficient
did not detect any correlation between α-synolig or the α-synolig/α-syntotal ratio and the PD
patients’ clinical data.
Fig 2. Correlations of total a-syn with PD patients’ clinical features. Scatter-plots showing the correlation between α-syntotal and patients’ disease
duration (DD) (panel A), Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) (part 1–4) (panel B), Montreal Cognitive
Assessment (MOCA) (panel C) and Frontal Assessment Battery (FAB) scores (panel D) in patients with PD.
doi:10.1371/journal.pone.0151156.g002
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Discussion
In the present study, we found that salivary a-syntotal is significantly lower in patients with PD
than in healthy subjects. Conversely, salivary a-synolig levels are higher in patients with PD
than in healthy subjects. Accordingly, the a-synolig/a-syntotal ratio is significantly higher in
patients with PD than in healthy subjects. We also found a negative correlation between sali-
vary a-syntotal and a-synolig, as well as correlation between a-syntotal and several clinical features
of the patients studied.
We made every effort to ensure that the patients with PD had varying degrees of disease
severity (H&Y stage I to III) and disease duration (range 1 to 28 years). Any PD patient or
healthy subject affected by other systemic diseases such as diabetes, cardiovascular diseases,
autoimmune diseases or chronic inflammatory diseases, in whom oxidative stress and a-syn
misfolding may occur, were excluded. Blood contamination of the samples, which is known to
affect the significance of a-syn detection [33], was carefully avoided. Moreover, we used two
commercial ELISA kits, one designed for a-syn and already used to detect a-syntotal in saliva
[25] and another, specifically designed to detect a-synolig (see data in S1 Text) in serum and
biological fluids.
The first finding in this study, on a large cohort of PD patients and healthy subjects, is the
reduction in a-syntotal in the saliva of patients with PD compared with healthy subjects. This
finding is fully in agreement with two previous observations in relatively small cohorts of
patients with PD [24,25]. It is important to note that determination of a-syntotal through ELISA
or Immuno-essay, as performed in this paper and in previous studies [24,25], likely underesti-
mate the total a-syn concentration in the saliva. Since the antibodies generally used to detect a-
syntotal are aimed at linear epitopes on the molecule of a-syn, antibodies may only detect the
unaggregated forms of the protein. By contrast, these antibodies may fail to detect aggregated
forms of a-syn, such as a-synolig, owing to the masking of epitopes by changes in the three-
dimensional conformation of the protein, leading to a-syn aggregation. In the present study,
we therefore considered the a-syntotal concentration largely as an estimate of the a-synmon, and
we used a different ELISA kit, specifically designed for oligomers of a-syn,to detect a-synolig,.
The reduction in salivary a-syntotal, and therefore in a-synmon, in patients with PD compared
with healthy subjects may be explained by considering a-syn aggregation. Neuropathological
studies have shown that in the early stages of PD intracellular aggregation of a-syn occurs in
several brainstem nuclei, including the solitary tract nucleus, the dorsal motor nucleus of vagus
[3,34] and probably the superior and inferior salivary nuclei and the parasympathetic salivary
ganglia [34]. It suggests that a-syn may spread from neuronal cell bodies of salivary neurons,
along axons, to the synaptic terminals around the epithelial cells of salivary glands, where it
also accumulates in the saliva [24,25]. It is therefore possible that the reduced a-syntotal concen-
tration detected in the saliva of patients with PD is due to an intracellular and axonal aggrega-
tion of a-syn in the neurons of the salivary nuclei or salivary ganglia.
A novel finding in this study is that, unlike a-syntotal and therefore a-synmon, the concentra-
tion of salivary a-synolig is higher in PD patients than in healthy subjects. Accordingly, the a-
synolig/a-syntotal ratio was also higher in PD patients than in healthy subjects. Pathogenetic
mechanisms may explain the increased concentration of synolig observed in the saliva of PD
patients. Indeed, in physiological conditions, there is equilibrium between monomers and olig-
omers of a-syn that reflects the efficacy of the cellular cleaning mechanisms from aggregated
and misfolded proteins [35,36]. In patients with PD, there is an altered turnover of a-syn [37],
leading to the accumulation of a-synolig at both the intracellular and extracellular levels. More-
over, we found that the concentration of salivary a-syntotal negatively correlates with that of a-
synolig, which further supports the hypothesis that a-synmon are reduced in the saliva of PD
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patients because a-synmon are consumed during the formation of a-syn aggregates, including a-
synolig. A-synolig are multimeric, aggregated forms of a-syn, with an higher molecular weight
than a-synmon (unaggregated forms of a-syn), explaining the salivary concentration in ng
rather than in pg as reported for a-syntotal, which may estimate, in turn, essentially a-synmon.
In patients with PD, we found a positive correlation between a-syntotal and disease duration,
H&Y, MDS-UPDRS (part 1–4) total score and LEDDs, and a negative correlation between a-syn-
total and the MOCA and FAB scores. A possible explanation for these findings is that, as the dis-
ease progresses, increased synaptic degeneration leads to an increased extracellular release of a-
syn into the interstitial fluids, including saliva. Our results do not support the trend of negative
correlation between a-syntotal concentration in saliva andMDS-UPDRS previously reported by
Devic and coworkers [24]. The reason for these variable results may reflect methodological differ-
ences including the different number of patients studied. Furthermore, the observation that sali-
vary a-syntotal concentration is lower in patients with a lower H&Y andMDS-UPDRS scores
(early stages of the disease) than in patients with higher H&Y andMDS-UPDRS scores (late stages
of the disease) suggest that the evaluation of salivary a-syntotal concentration might be an helpful
tool in the diagnosis of PD particularly in the early stage of the disease. Despite a-syntotal, we failed
to detect a correlation between a-synolig in saliva and the clinical features of the PD patients. This
finding is difficult to explain. A possible explanation could be the well-known molecular heteroge-
neity of a-synolig [12,37]. This could lead to a widespread variability of a-synolig conformation in
the saliva of PD patients at different stages of the disease. In line with this hypothesis, further stud-
ies of molecular biology may be needed to detect the different “subclasses” of a-synolig in saliva
and the correlation of each of them with clinical features of PD patients.
The data on saliva that emerge from our study are in keeping with those reported in previous
studies based on CSF [13,14,15,16]. Moreover, the correlations between salivary a-syntotal and
clinical severity scores are supported by recent reports in CSF, in which higher levels of α-syntotal
correlate with a worsening in both motor symptoms [38] and cognitive performances [39].
Besides the previous studies on a-syntotal our finding of increased a-synolig levels in the saliva of
PD patients is fully in line with the results of previous papers [26,27,40], who reported that a-
synolig levels are significantly higher in the CSF of PD patients than in that of healthy subjects.
Our results are also in keeping with recent studies showing increased concentration of pathologi-
cal aggregated forms of a-syn in the CSF of PD patients [41], using a new monoclonal antibody
(5G4 a-syn) specific for aggregated forms of a-syn. Conversely, by using the same 5G4 a-syn anti-
body in the serum of PD patients, Maetzler et al. (2014) [42] found comparable concentration of
5G4 a-syn and a-syntotal. Since CSF and saliva, but not serum, are fluids in contact with neuronal
fibers and therefore likely affected by a-syn secretion, the serum concentration of different forms
of a-syn is difficult to compare with those measured in CSF and saliva. The results obtained from
CSF and saliva may confirm that the oligomeric form of a-syn is the prevalent a-syn species in
the extracellular fluids of PD patients and that a-syntotal levels are reduced following the forma-
tion of a-syn aggregates and the consequent reduction in a-synmon.
Our study has certain important limitations. We found that a-syntotal and a-synolig concen-
trations overlap in some healthy subjects and PD patients. Moreover, some biochemical limita-
tions may affect the ELISA analysis of salivary samples. First, saliva is a biological fluid that
contains proteolytic and glycolytic enzymes, possibly influencing the concentration of a-syn in
saliva through proteolitic digestion. Although we used a specific protease inhibitor to prevent
enzymatic digestion of proteins and intermolecular bonds, some residual enzymatic activity
may be still present. Second, a-synolig are heterogeneous and unstable molecules that are altered
by dissociation and conformational changes [37], which may therefore markedly, and unpre-
dictably, affect antigen-antibody binding. Therefore, a misleading by antibodies used and a
cross-reaction with a-synmon cannot be excluded, despite the specificity of the ELISA kit used
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for the detection of a-synolig. In addition, it is known that a-synolig may be differentiated in sev-
eral subclasses and the different aggregation mechanisms of a-syn lead to the lipophilic nature
of specific subclasses of a-synolig [7,12]. It is difficult however, to measure lipophilic aggregates
of a-syn such as large beta-sheet aggregates of a-syn in solutions. The lack of detection of lipo-
philic a-synolig is a limitation of the study. Finally, although the ELISA kits we used were not
specifically validated for saliva, it is important to note that these ELISA kits have been validated
in serum and biological fluids, as reported in the data sheet of the products. Furthermore,
when testing saliva, we used all precautions to avoid methodological drawbacks due to the spe-
cific biophysical and biochemical characteristics of saliva including application of proteolytic
inhibitor to prevent the action of proteolytic enzymes of saliva on the proteins.
Previous studies have demonstrated that, in the early stage of PD, patients may manifest
hyposialorrhea, whereas in more advanced stage of the disease, patients may manifest hypersia-
lorrhea [43,44]. Accordingly, in patients with PD, abnormal salivary secretion in terms of vol-
ume and composition [43,44] might influence the salivary concentration of a-syntotal and a-
synolig. This hypothesis seems, however, unlikely because in our study we found a lack of corre-
lation between a-syntotal and a-synolig and sialorrhea as scored by the MDS-UPDRS item 2.2.
This finding suggests that concentration of a-syn in saliva is not related to salivary secretion
rate. However, future investigations correlating objective salivary secretion scores [43] and sali-
vary a-syntotal and a-synolig concentration will help to clarify whether salivary a-syntotal and a-
synolig also reflect the salivary secretion rate in PD.
In conclusion, although our study was performed by ELISA kits not specifically validated in
saliva, our results suggest that salivary a-syntotal is reduced in patients affected by PD and pro-
vides the first evidence that both a-synolig levels and the a-synolig/a-syntotal ratio are increased
in the saliva of PD patients. Considering the heterogeneity of a-synolig, comparative studies
with different anti-oligomeric a-syn specific antibodies are needed to definitively confirm our
data. Further studies are required to confirm whether a-syn in saliva may be used as a bio-
marker for PD [45] and whether it correlates with disease progression and severity. Future
studies will clarify whether the combined analysis of a-syntotal and a-synolig in the saliva might
help the early diagnosis of PD and the differential diagnosis between PD and atypical parkin-
sonisms including Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP).
Supporting Information
S1 Table. Clinical data of PD patients enrolled in the study.
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